IFRX
$0.91
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoi...
Recent News
InflaRx Showcases Izicopan HS and CSU Data, Streamlines C5aR Strategy at Oppenheimer Conference
InflaRx (NASDAQ:IFRX) highlighted recent clinical updates and strategic priorities for its complement inhibition platform during a presentation at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference. CEO Niels C. Riedemann said the company has recently streamlined its corporate strategy to
InflaRx Spotlights Izicopan HS Data, Phase 2b Plans and 30% Cost Cuts at Guggenheim Summit
InflaRx (NASDAQ:IFRX) highlighted progress on its oral C5a receptor 1 (C5aR) antagonist izicopan and outlined upcoming development plans during a presentation at the Guggenheim Outlook Biotech Summit 2026. Chief Financial Officer Thomas Taapken and investor relations executive Jan Medina also discus
Here's Why InflaRx (NASDAQ:IFRX) Must Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
InflaRx (IFRX) Is Up 17.7% After INF904 Shows Promising Results in Phase 2a Study—What's Changed
InflaRx recently announced positive topline data from its Phase 2a basket study of oral C5aR inhibitor INF904 in hidradenitis suppurativa and chronic spontaneous urticaria, with rapid and durable improvements in clinical endpoints and no serious adverse events reported. An interesting insight is that efficacy measures for INF904 compared favorably with those of currently approved therapies, with continued benefits seen even after treatment ended. We'll explore how these promising efficacy...
BC-Most Active Stocks
EPWK Holdings Ltd. 22,317,574 0.0719